926 related articles for article (PubMed ID: 18036392)
1. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007; 29 Spec No():1306-15. PubMed ID: 18046930
[TBL] [Abstract][Full Text] [Related]
3. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
4. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
5. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
6. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
[TBL] [Abstract][Full Text] [Related]
7. Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes.
Wu J; Seiber E; Lacombe VA; Nahata MC; Balkrishnan R
Ann Pharmacother; 2011 Mar; 45(3):342-9. PubMed ID: 21325098
[TBL] [Abstract][Full Text] [Related]
8. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.
Herman WH; Dirani RG; Horblyuk R; O'Neill MC; Kravitz B; Heise MA; Bakst A; Freed MI;
Am J Manag Care; 2005 Apr; 11(4):273-8. PubMed ID: 15839187
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
10. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
Hansen RA; Farley JF; Droege M; Maciejewski ML
Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
[TBL] [Abstract][Full Text] [Related]
11. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis.
Balkrishnan R; Rajagopalan R; Shenolikar RA; Camacho FT; Whitmire JT; Anderson RT
Curr Med Res Opin; 2004 Oct; 20(10):1633-40. PubMed ID: 15462696
[TBL] [Abstract][Full Text] [Related]
12. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
13. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
14. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients.
Cheong C; Barner JC; Lawson KA; Johnsrud MT
Clin Ther; 2008 Oct; 30(10):1893-907. PubMed ID: 19014846
[TBL] [Abstract][Full Text] [Related]
15. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
16. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
Barner JC
Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
[TBL] [Abstract][Full Text] [Related]
17. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients.
Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
Med Care; 2008 Nov; 46(11):1125-33. PubMed ID: 18953222
[TBL] [Abstract][Full Text] [Related]
18. Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis.
Balkrishnan R; Rajagopalan R; Shenolikar RA; Camacho FT; Anderson RT
Curr Med Res Opin; 2006 Mar; 22(3):551-9. PubMed ID: 16574038
[TBL] [Abstract][Full Text] [Related]
19. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
20. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
